Trial · NCT00795288
Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)
NCT00795288, Phase 1, Phase 2, Completed, Washington University School of Medicine; results first posted 2015-01-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH). Trials, record NCT00795288. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00795288
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)
- NCT number
- NCT00795288
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 42 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Subarachnoid Hemorrhage
- Interventions
- Simvastatin, 80 mg/day for 21 days, placebo
- First posted
- 2008-11-21
- Last updated
- 2016-03-21
- Results first posted
- 2015-01-16
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk | 7-10 days after hemorrhage | Resting cerebral blood flow during peak period of vasospasm risk measured by PET |
| Primary | Cerebral Autoregulation During Peak Period of Vasospasm Risk | 7-10 days after hemorrhage | Fraction of patients with impaired static autoregulation (% change in MAP/% change in CVR) \* 100 A value of \<60 is considered abnormal. |
| Secondary | Impact of Statin on Oxygen Extraction Fraction and Cerebral Metabolism During Peak Period of Vasospasm Risk | 7-10 days after hemorrhage | Oxygen extraction fraction (OEF) is the ratio of Oxygen delivery (ml/100 g/min) and oxygen utilization (ml/100 g/min). It describes the fraction of the oxygen that reaches the brain that it actually uses for energy production. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk | 7-10 days after hemorrhage | Of the total population enrolled complete data sets were available on 25. This was due to patient refusal to perform the PET study, logistical difficulties and technical problems.~be completed in seven due to logistical difficulties (n = 4) or patient refusal (n = 3). Two of the completed studies could not be analyzed for technical reasons | mL/100 g/min | MEAN |
| PRIMARY | Cerebral Autoregulation During Peak Period of Vasospasm Risk | 7-10 days after hemorrhage | participants | NUMBER | |
| SECONDARY | Impact of Statin on Oxygen Extraction Fraction and Cerebral Metabolism During Peak Period of Vasospasm Risk | 7-10 days after hemorrhage | ratio | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk | Simvastatin | .34 | Standard Deviation 0.1 | mL/100 g/min | |
| Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk | Control | .30 | Standard Deviation .18 | mL/100 g/min | |
| Cerebral Autoregulation During Peak Period of Vasospasm Risk | Simvastatin | 2 | participants | ||
| Cerebral Autoregulation During Peak Period of Vasospasm Risk | Control | 2 | participants | ||
| Impact of Statin on Oxygen Extraction Fraction and Cerebral Metabolism During Peak Period of Vasospasm Risk | Simvastatin, 80 mg/Day | .34 | Standard Deviation .1 | ratio | |
| Impact of Statin on Oxygen Extraction Fraction and Cerebral Metabolism During Peak Period of Vasospasm Risk | Placebo | .3 | Standard Deviation .18 | ratio |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 21 | |
| Overall Study | STARTED | Simvastatin | 21 | |
| Overall Study | COMPLETED | Placebo | 21 | |
| Overall Study | COMPLETED | Simvastatin | 21 | |
| Overall Study | NOT COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Simvastatin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Simvastatin | ||
| Total, all-cause mortality | Control | ||
| Total, other adverse events | Simvastatin | 0 | 21 |
| Total, other adverse events | Control | 0 | 21 |
| Total, serious adverse events | Simvastatin | 0 | 21 |
| Total, serious adverse events | Control | 0 | 21 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26721259 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Simvastatin vs Control: Cerebral Autoregulation During Peak Period of Vasospasm Risk | Trial comparisons |
| Simvastatin vs Control: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00795288
GET https://conductscience.org/api/trials/v1/NCT00795288/registered